Catalyst Dossier · compiled by CeliA 🧫
Pacira BioSciences, Inc. (PCRX)
Pharmaceutical Preparations · market cap $879M · as of 2026-07-20
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2026-11-15 (est.)
Phase 2
Pipeline
20
programs
Upcoming events
2
next 90d+
Dossier
Ready
cached
Pacira BioSciences (PCRX) is a ~$1B market cap specialty pharma company with 788 employees focused on non-opioid pain management and musculoskeletal disease, anchored by its marketed EXPAREL (bupivacaine liposome) and ZILRETTA (triamcinolone acetonide extended-release) franchises. The company generated $726M in revenue in 2025 with a thin $7M net profit, carries $223M net debt against $144M cash, and faces a pivotal 2026 binary with two high-importance Phase 3 ZILRETTA readouts in new indications. A deep pipeline including the gene therapy PCRX-201 and multiple SKY0402 programs adds optionality but also complexity.
The catalyst path
- 2026-11-15 (est.)Phase 2 · Enekinragene Inzadenovec (PCRX-201)imp 7/10
- 2026-12-15 (est.)Phase 3 · ZILRETTAimp 9/10
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| SKY0402 | Phase 3 | Hemorrhoid |
| FX006 | Phase 3 | Osteoarthritis of the Knee |
| FX005 | Phase 2 | Osteoarthritis, Knee |
| Bupivacaine liposome | Phase 3 | Dental Pain |
| EXPAREL 266 mg | Phase 3 | Posterolateral Thoracotomy |
| SKY0402 + bupivacaine HCl | Phase 2 | Postoperative Pain |
| Bupivacaine HCl | Phase 3 | Postoperative Pain |
| FX006 16 mg | Phase 2 | Osteoarthritis of the Knee |
| FX006 10 mg | Phase 2 | Osteoarthritis of the Knee |
| FX006 32 mg | Phase 3 | Osteoarthritis of the Shoulder |
| EXPAREL 67 mg | Phase 3 | Postoperative Pain |
| ZILRETTA | Phase 3 | Glenohumeral Osteoarthritis |
| Exparel | Phase 3 | Postoperative Pain Management |
| Enekinragene Inzadenovec (PCRX-201) | Phase 2 | Osteoarthritis (OA) of the Knee |
| Bupivacaine liposome injectable suspension 266 mg | Phase 3 | Bunionectomy |
| bupivacaine liposome injectable suspension | Phase 3 | Pain |
| TCA IR 40 mg | Phase 2 | Osteoarthritis of the Knee |
| Bupivacaine Hydrochloride | Phase 3 | Lower Extremity Surgery |
| TAcs 40 mg | Phase 2 | Bilateral Knee Osteoarthritis |
| TCA IR 40 | Phase 3 | Osteoarthritis of the Knee |
Price & technical context
3-month
+7.7%
6-month
+10.4%
12-month
-0.9%
52-wk range
$19.16–$27.62
vs 50-day MA
+3.6%
vs 200-day MA
+9.1%
Realized vol
39.3%
Max drawdown
-30.4%
Daily closes through 2026-08-26. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for PCRX (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 20 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.